The landscape of diabetes care is undergoing a exciting change with the introduction of rapidly disintegrating GLP-1 therapies. These innovative formulations, designed to instantly dissolve under the tongue, offer the potential for faster absorption and a minimized need for daily injections. This strategy could optimize patient compliance and maybe

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these fast and rapid weight loss products vital therapeutic agents. The agreement enables them to han